DDX5 enables LMTK3 to facilitate the processing of pri-miRNAs (pri-miR-34a, pri-miR-182, and pri-miR-196-a2) for maturation, and upregulated miR-34a and miR-182 can target and inhibit LMTK3 expression, consequently suppressing the oncogenic effects of LMTK3 in breast cancer. Here, DDX5 is linked to breast carcinoma.